Primary sclerosing cholangitis: diagnosis and management

Area of Science:

• Hepatology
• Immunology
• Gastroenterology

Background:

• Primary sclerosing cholangitis (PSC) is a chronic, progressive liver disease characterized by inflammation and destruction of bile ducts.
• PSC is strongly associated with ulcerative colitis and is considered an autoimmune condition involving genetic predisposition and immune dysregulation.
• The homing of memory lymphocytes to the biliary tract is a proposed mechanism in PSC pathogenesis.

Purpose of the Study:

• To review the current understanding of Primary Sclerosing Cholangitis (PSC).
• To discuss diagnostic standards and therapeutic approaches for PSC.
• To highlight ongoing research and future directions in PSC management.

Main Methods:

• Diagnosis relies on cholangiography, revealing characteristic strictures and dilations in the biliary tract.
• Review of existing literature on PSC pathogenesis, diagnosis, and treatment.
• Discussion of ongoing clinical trials, including the use of high-dose ursodeoxycholic acid.

Main Results:

• Cholangiography is the gold standard for diagnosing PSC, showing multifocal strictures and dilations.
• No definitive medical therapy has proven universally effective, though some agents show promise.
• High-dose ursodeoxycholic acid is under investigation for its potential to slow disease progression.

Conclusions:

• PSC is a complex autoimmune liver disease requiring further research into effective treatments.
• Liver transplantation offers a viable option for end-stage PSC, but disease recurrence is a concern.
• Continued investigation into immunomodulatory therapies and supportive care is crucial for improving PSC patient outcomes.